Ideas
AI memory fundamentals solid, selloff overdone
AI memory chip stocks (Sandisk, Western Digital, SK hynix) are growing triple digits; while pricing growth has likely peaked, volume growth remains strong and Q2 capex trends suggest continued investment. The selloff is market-driven, not fundamental, and the companies are still fundamentally sound.
Hyperscaler capex tailwinds for AI infrastructure
Hyperscalers including SpaceX are planning massive capex for gigawatt-scale AI infrastructure, with SpaceX aspiring to $100B ARR and willing to invest heavily. This ongoing investment cycle is a positive for AI infrastructure plays, regardless of ROI questions, because infrastructure providers will keep getting investments.
WBD strong with merger optionality or termination fee
Warner Bros. Discovery's fundamental story is in good shape with profitable streaming and margin improvements. The Paramount-Skydance merger risk provides a floor: if the deal expires and doesn't close, WBD collects $7 billion in termination fees, putting it in a strong position either way.
Diversify internationally away from US tech
The AI trade is broadening beyond the Magnificent 7, and investors are overly concentrated in US large-cap tech. Diversifying into developed international and emerging markets is essential because many forget those markets exist and offer return opportunities.
Krispy Kreme turnaround driving margin and growth
Krispy Kreme's turnaround is working: margins improved 340 basis points, leverage was paid down 1.3 turns, and underlying revenue grew 4.4% excluding the exited McDonald's distribution. The company is well positioned with strong brand engagement and will continue margin improvement alongside growth.
Non-tech sectors offer better growth opportunities
There is a lot of opportunity outside the tech space, particularly in industrials, defense, and banks. Industrials first-quarter earnings were up 20% versus expectations of 3%, and these high-quality names have been ignored for years, offering attractive entry points for growth.
Roivant near FDA approval for orphan drug
Roivant expects FDA approval for its lead orphan-disease drug this quarter, with launch by end of September. The drug addresses a disease with no other options and showed strong clinical data, providing a significant first-in-class opportunity despite no current revenue.
Oil supply risk from Hormuz and Red Sea
Brent crude is rising due to heightened geopolitical risks: an Iran-Oman Strait of Hormuz agreement is only temporary, doesn't guarantee full reopening, and does not address Iran's nuclear program. Additionally, Houthi attacks on Saudi-allied forces raise Red Sea choke-point risks, keeping supply disruption fears alive.
This Bloomberg Markets video, published August 06, 2026,
features Mandeep Singh, Geetha, Emily Green, Josh Charlesworth, Alex Chaloff, Matt Gline, Kailey Leinz
discussing SNDK, WDC, 000660.KS, AI Infrastructure & Semiconductors, WBD, EFA, EEM, DNUT, ITA, KBE, XLI, Roivant, BNO.
8 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Mandeep Singh,
Geetha,
Emily Green,
Josh Charlesworth,
Alex Chaloff,
Matt Gline,
Kailey Leinz
· Tickers:
SNDK,
WDC,
000660.KS,
AI Infrastructure & Semiconductors,
WBD,
EFA,
EEM,
DNUT,
ITA,
KBE,
XLI,
Roivant,
BNO